A special issue of Positively Aware magazine focusing on PrEP (pre-exposure prophylaxis) for helping to prevent HIV is now available, both in print and online at positivelyaware.com.
The 24-page issue was supported by an unrestricted educational grant from Gilead Sciences, Inc.
PrEP is when medicines are used before possible exposures to HIV to prevent infection. Truvada, originally approved to treat HIV/AIDS in combination with other antiretrovirals in 2004, is composed of two medications, emtricitabine and tenofovir DF, and was approved for use in PrEP in 2012.
Contributors to the issue include Robert Grant, MD, MPH, senior investigator at the Gladstone Institutes and a Professor of Medicine at University of California, San Francisco, and senior investigator of the iPrEx study, one of the pivotal studies which led to approval of Truvada for PrEP. Grant states in his article that antiretroviral therapy has revolutionized care for people living with HIV/AIDS, and these same medications can be taken by HIV-negative people with the goal of staying free of HIV, which has led to unprecedented optimism about the prospect of ending AIDS.
The Chicago-based HIV/AIDS organization Test Positive Aware Network (TPAN) publishes Positively Aware. To order copies of the magazine, call 773-989-9400 or email distribution@tpan.com.